Entity

Time filter

Source Type

Ymittos Athens, Greece

Grech V.-S.,University of Pecs | Grech M.,Childrens Hospital Aglaia Kyriakou | Togias A.,General Hospital of Kalamata | Grech I.,Technological Educational Institute of Athens
Review of Clinical Pharmacology and Pharmacokinetics, International Edition | Year: 2012

Alzheimer's Disease (AD) is the most prevalent form of Dementia, which is a gradual loss of memory, judgment, and ability to function and the sixth leading cause of death in Developed World. This disorder usually appears in people older than age 65, but less common forms of the disease appear earlier in adulthood. Research advances have enabled detailed understanding of the molecular pathogenesis of the hallmarks of the disease, i.e., plaques, composed of amyloid bet, and tangles, composed of hyperphosphorylated tau. Mutations in the amyloid precursor protein, presenilin 1 and presenilin 2 genes cause autosomal dominant familial Alzheimer's disease (AD). PSEN1 and PSEN2 are essential components of the gamma-secretase complex, which cleaves APP to affect Abeta processing. Recent advances in developmental and stem cell biology have made regenerationbased therapies feasible as therapeutic strategies for patients with damaged central nervous systems, including those with spinal cord injuries, Parkinson disease, or stroke. This review provides information meant to increase an understanding of the public-health impact of AD, including incidence and prevalence, mortality, lifetime risks, costs, impact on family caregivers, AD neuropathology, endogenous neurogenesis in adult brain and future prospects. © PHARMAKON-Press. Source


Kotoula V.,Aristotle University of Thessaloniki | Kotoula V.,Hellenic Foundation for Cancer Research | Bobos M.,Hellenic Foundation for Cancer Research | Vassilakopoulou M.,Yale University | And 11 more authors.
Applied Immunohistochemistry and Molecular Morphology | Year: 2015

Anaplastic lymphoma kinase (ALK) break-apart fluorescent in situ hybridization (FISH) is currently used in diagnostics for the selection of non-small cell lung cancer (NSCLC) patients to receive crizotinib. We evaluated ALK status in NSCLC with a novel ALK mRNA test based on the break-apart FISH concept, which we called break-apart transcript (BAT) test. ALK50 and ALK30 transcript patterns were established with qPCR for ALK-expressing controls including fusion-negative neuroblastomas, as well as fusion-positive anaplastic large cell lymphomas and NSCLC. The BAT test was evaluated on 271 RNA samples from routinely processed paraffin NSCLC tissues. Test results were compared with ALK FISH (n=121), immunohistochemical (IHC) analysis (n=86), and automated quantitative analysis (AQUA, n=83). On the basis of the nonoverlapping ALK BAT patterns in ALK-expressing controls (P<0.0001), 8/174 adenocarcinomas (4.6%) among 259 informative NSCLC were predicted as fusion positive. Overall concordance for paired method results was high (94.1% to 98.8%) but mainly concerned negative prediction because of the limited availability of positive-matched cases. Tumors with 100% cytoplasmic IHC staining of any intensity (n=3) were positive for AQUA, FISH, and BAT test; tumors with lower IHC positivity and different staining patterns were AQUAnegative. Upon multiple reevaluations, ALK gene status was considered as originally misinterpreted by FISH in 3/121 cases (2.5%). Tumors with >4 ALK gene copies were associated with longer overall survival upon first-line chemotherapy. In conclusion, application of the ALK BAT test on routinely processed NSCLC tissues yields the same fusion partner independent information as ALK break-apart FISH but is more robust and cost-effective. The BAT concept may be considered for the development of further drug-predictive translocation tests. Copyright © 2014 by Lippincott Williams & Wilkins. Source


Goussetis E.,Stem Cell Transplant Unit | Constantoulakis P.,Locus Medicus Laboratories | Kitra V.,Stem Cell Transplant Unit | Peristeri I.,Stem Cell Transplant Unit | And 7 more authors.
Pediatric Blood and Cancer | Year: 2011

We report successful bone marrow transplantation in an 11-year-old male with chronic myeloid leukemia from his HLA-identical sibling selected by preimplantation HLA testing. Because collection of cord blood failed, the transplantation was performed when the donor reached the age of 19 months, and sufficient bone marrow could be harvested safely. The patient was BCR/ABL negative at the time of transplantation after complete molecular response to imatinib. Currently, 16 months post-transplantation he is well and in complete molecular remission. This report describes preimplantation HLA-genotyping to deliver a matched sibling donor for successful transplantation of a malignant disorder. © 2011 Wiley-Liss, Inc. Source

Discover hidden collaborations